Salivary Gland Cancer

P=N/A, N=0, Recruiting, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine; Shanghai Ninth People's Hospital, Shanghai Jiaotong University Scho

T-DXd has emerged as a transformative therapy across HER2-driven malignancies, leading to histology-specific and tissue-agnostic approvals. Vigilant ILD monitoring is essential, and further research is warranted to refine biomarkers, address resistance, and explore rational drug combinations. T-DXd exemplifies the paradigm shift of antibody-drug conjugates toward pan-cancer precision oncology.

Although HER2-positive (3 +) was seen only in SDC, HER2-low and HER2-ultra-low expressions were not uncommon across salivary gland carcinomas, including SDCs and various non-SDC types. These findings suggest the potential applicability of HER2-targeted therapy in salivary gland carcinomas.

We report the case of a middle-aged man with HER2-positive metastatic SDC who achieved near-complete pathologic and radiological response to trastuzumab and docetaxel, enabling surgical resection for locoregional control. This case highlights the role of anti-HER2 therapy as a first-line strategy in SDC and underscores the importance of individualized management plans integrating systemic treatment and locoregional measures.

Thus, the potential for AGE10 as a diagnostic marker is limited. The implications concern the biology of this epitope, the unique tissue distribution, and a role in cellular metabolism.

The impact of immunohistochemical or molecular markers on treatment selection and response was most pronounced in SDC. HER2 IHC2 + expression was observed across multiple subtypes, indicating that TDxd may represent a potential treatment option for more pts than previously anticipated. The impact of comprehensive genomic profiling on targeted treatment options is currently still modest.

Intraductal salivary gland neoplasms present diagnostic challenges due to their overlapping clinical and histologic features. Understanding of the characteristic morphologic and immunophenotypic profile of IDC is essential for accurate diagnosis and appropriate patient management.

The absence of the common MEC-associated fusion gene may indicate a more aggressive clinical course. Further accumulation of cases with detailed molecular characterization is crucial to clarify the pathogenesis, behavior, and optimal management strategies for this rare entity.

P1, N=30, Recruiting, Brigham and Women's Hospital | Trial completion date: Nov 2031 --> Aug 2029 | Trial primary completion date: Mar 2031 --> Apr 2029

Cancer surgery, radiotherapy, parotidectomy, neck dissection, chemotherapy, and cisplatin were the keywords of treatment...There have always been the common keywords such as pathology, tumor marker, immunohistochemistry, Ki-67, CRTC1, MAML2, gene fusion, and fluorescence in situ hybridization (FISH). This study for the first time elucidated the current scenario and scientometric characteristics of MEC, and would help in improving in reciprocal collaboration and provide helpful guidance for further research.

P1/2, N=41, Active, not recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Jun 2026 --> Nov 2026 | Trial primary completion date: Dec 2025 --> May 2026

Combined use of LEF1 and β-catenin improved sensitivity (90%) but resulted in a medium specificity (93%). In conclusion, the proposed immunohistochemical panel can improve diagnostic accuracy in basaloid tumors of the salivary glands.